Published: 18. November, 2022
Cessatech today releases its results for the period 1 July – 30 September 2022….
Cessatech today releases its results for the period 1 July – 30 September 2022. The Company is progressing well with planned activities, successful outcome of trial 0206 and first patient dosed in pivotal trial 0205 (a randomised double-blind placebo-controlled trial with 220 patients in adult following impacted mandibular third molar extraction).
“During the third quarter of 2022 we announced the successful outcome of our Phase 2 trial 0206, the pharmacokinetic study with CT001 and very importantly, we initiated our pivotal trial 0205, a randomised double-blind placebo-controlled study with 220 patients with dosing of the first patient. We are now in an exclusive group of selected companies in late stage development, great effort from the team and our partners“, says Jes Trygved, CEO